Pathstone Family Office’s Teva Pharmaceuticals TEVA Stock Holding History

Pathstone Family Office’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$638K	Buy	+62,564	New	+$583K	﹤0.01%	930
2023 Q1	–	Sell	-11,780	Closed	-$632K	–	1487
2022 Q4	$632K	Sell	11,780 -8,474	-42%	-$73.9K	0.01%	994
2022 Q3	$164K	Buy	+20,254	New	+$179K	﹤0.01%	1376
2021 Q1	–	Sell	-519	Closed	-$5K	–	1285
2020 Q4	$5K	Sell	519 -3,000	-85%	-$28.7K	﹤0.01%	961
2020 Q3	$32K	Buy	3,519 +3,000	+578%	+$31.7K	﹤0.01%	417
2020 Q2	$6K	Hold	519	–	–	﹤0.01%	565
2020 Q1	$5K	Buy	+519	New	+$5.32K	﹤0.01%	622
2019 Q4	–	Sell	-519	Closed	-$4K	–	613
2019 Q3	$4K	Hold	519	–	–	﹤0.01%	550
2019 Q2	$5K	Hold	519	–	–	﹤0.01%	564
2019 Q1	$8K	Hold	519	–	–	﹤0.01%	543
2018 Q4	$8K	Buy	519 +309	+147%	+$6.33K	﹤0.01%	352
2018 Q3	$5K	Buy	+210	New	+$4.88K	﹤0.01%	184
2014 Q4	–	Sell	-265	Closed	-$14K	–	244
2014 Q3	$14K	Buy	+265	New	+$14K	0.04%	183

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Pathstone Family Office's TEVA Position: Q3 2023 in Review

Pathstone Family Office opened a new position in Teva Pharmaceuticals (TEVA) in Q3 2023: 62,564 shares worth $638K. The stake represents ﹤0.01% of the portfolio and ranks #930 among its holdings. This is a return to the name: Pathstone Family Office previously reported a position in TEVA as recently as Q4 2022.

Pathstone Family Office first reported a position in TEVA in Q3 2014 and has held it in 13 quarters since. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Pathstone Family Office held 62,564 shares of Teva Pharmaceuticals worth $638K as of Q3 2023.
Teva Pharmaceuticals was a new Pathstone Family Office position in Q3 2023.
Teva Pharmaceuticals made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #930 holding.
Pathstone Family Office first reported a position in Teva Pharmaceuticals in Q3 2014 and has held it in 13 quarters since.
435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.